Literature DB >> 19360911

Bile-acid-induced cell injury and protection.

Maria-J Perez1, Oscar Briz.   

Abstract

Several studies have characterized the cellular and molecular mechanisms of hepatocyte injury caused by the retention of hydrophobic bile acids (BAs) in cholestatic diseases. BAs may disrupt cell membranes through their detergent action on lipid components and can promote the generation of reactive oxygen species that, in turn, oxidatively modify lipids, proteins, and nucleic acids, and eventually cause hepatocyte necrosis and apoptosis. Several pathways are involved in triggering hepatocyte apoptosis. Toxic BAs can activate hepatocyte death receptors directly and induce oxidative damage, thereby causing mitochondrial dysfunction, and induce endoplasmic reticulum stress. When these compounds are taken up and accumulate inside biliary cells, they can also cause apoptosis. Regarding extrahepatic tissues, the accumulation of BAs in the systemic circulation may contribute to endothelial injury in the kidney and lungs. In gastrointestinal cells, BAs may behave as cancer promoters through an indirect mechanism involving oxidative stress and DNA damage, as well as acting as selection agents for apoptosis-resistant cells. The accumulation of BAs may have also deleterious effects on placental and fetal cells. However, other BAs, such as ursodeoxycholic acid, have been shown to modulate BA-induced injury in hepatocytes. The major beneficial effects of treatment with ursodeoxycholic acid are protection against cytotoxicity due to more toxic BAs; the stimulation of hepatobiliary secretion; antioxidant activity, due in part to an enhancement in glutathione levels; and the inhibition of liver cell apoptosis. Other natural BAs or their derivatives, such as cholyl-N-methylglycine or cholylsarcosine, have also aroused pharmacological interest owing to their protective properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360911      PMCID: PMC2668773          DOI: 10.3748/wjg.15.1677

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  121 in total

1.  Cerebrotendinous xanthomatosis: defective liver mitochondrial hydroxylation of chenodeoxycholic acid precursors.

Authors:  H Oftebro; I Björkhem; F C Størmer; J I Pedersen
Journal:  J Lipid Res       Date:  1981-05       Impact factor: 5.922

2.  Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.

Authors:  R Botla; J R Spivey; H Aguilar; S F Bronk; G J Gores
Journal:  J Pharmacol Exp Ther       Date:  1995-02       Impact factor: 4.030

3.  Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat.

Authors:  J Kountouras; B H Billing; P J Scheuer
Journal:  Br J Exp Pathol       Date:  1984-06

Review 4.  Pharmacology of ursodeoxycholic acid, an enterohepatic drug.

Authors:  A F Hofmann
Journal:  Scand J Gastroenterol Suppl       Date:  1994

Review 5.  Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis.

Authors:  A Stiehl
Journal:  Scand J Gastroenterol Suppl       Date:  1994

6.  Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes.

Authors:  T Patel; S F Bronk; G J Gores
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

7.  Ursodeoxycholic acid reduces the systemic toxicity of 1,2-dichloro,4-nitrobenzene by stimulating hepatic glutathione S-transferase in mice.

Authors:  K Kitani; S Kanai; Y Sato; M Ohta; M Nokubo
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

8.  Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids.

Authors:  A F Attili; M Angelico; A Cantafora; D Alvaro; L Capocaccia
Journal:  Med Hypotheses       Date:  1986-01       Impact factor: 1.538

9.  Hepatotoxic bile acids increase cytosolic Ca++ activity of isolated rat hepatocytes.

Authors:  M S Anwer; L R Engelking; K Nolan; D Sullivan; P Zimniak; R Lester
Journal:  Hepatology       Date:  1988 Jul-Aug       Impact factor: 17.425

10.  Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats.

Authors:  S Krähenbühl; C Talos; B H Lauterburg; J Reichen
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

View more
  207 in total

1.  The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis.

Authors:  Bradley P Sullivan; Paul H Weinreb; Shelia M Violette; James P Luyendyk
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  Specific bile acids inhibit hepatic fatty acid uptake in mice.

Authors:  Biao Nie; Hyo Min Park; Melissa Kazantzis; Min Lin; Amy Henkin; Stephanie Ng; Sujin Song; Yuli Chen; Heather Tran; Robin Lai; Chris Her; Jacquelyn J Maher; Barry M Forman; Andreas Stahl
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

3.  Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.

Authors:  Izna Ali; Seher Khalid; Bruno Stieger; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2019-01-25       Impact factor: 4.939

4.  Role of Organic Solute Transporter Alpha/Beta in Hepatotoxic Bile Acid Transport and Drug Interactions.

Authors:  James J Beaudoin; Jacqueline Bezençon; Noora Sjöstedt; John K Fallon; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

5.  Regulation of hepatic EAAT-2 glutamate transporter expression in human liver cholestasis.

Authors:  Mustapha Najimi; Xavier Stéphenne; Christine Sempoux; Etienne Sokal
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

6.  Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation.

Authors:  Eun Sun Jang; Jung-Hwan Yoon; Sung-Hee Lee; Soo-Mi Lee; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-27       Impact factor: 4.553

Review 7.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

8.  Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice.

Authors:  Benjamin L Woolbright; Daniel J Antoine; Rosalind E Jenkins; Mary Lynn Bajt; B Kevin Park; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2013-10-03       Impact factor: 4.219

Review 9.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

10.  Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.

Authors:  Patricia A Thompson; Betsy C Wertheim; Denise J Roe; Erin L Ashbeck; Elizabeth T Jacobs; Peter Lance; María Elena Martínez; David S Alberts
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.